| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
6,360,000 |
| Market
Cap: |
7.63(M) |
| Last
Volume: |
43,465 |
Avg
Vol: |
33,933 |
| 52
Week Range: |
$0.709386 - $2.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cyclo Therapeutics is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. Co.'s primary drug candidate, Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), is used as a treatment for Niemann-Pick Type C disease (NPC). NPC is a cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. Co. is also exploring the use of cyclodextrins in the treatment of Alzheimer's disease. Co. sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
4,000,000 |
4,464,105 |
| Total Buy Value |
$0 |
$0 |
$5,000,000 |
$5,349,498 |
| Total People Bought |
0 |
0 |
1 |
5 |
| Total Buy Transactions |
0 |
0 |
1 |
10 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fine N Scott |
Chief Executive Officer |
• • – |
2021-09-15 |
4 |
B |
$6.35 |
$31,750 |
D/D |
5,000 |
114,666 |
2.81 |
-42% |
|
| Ostronic Francis Patrick |
Director |
• • – |
2021-04-16 |
4 |
B |
$6.30 |
$65,250 |
D/D |
10,000 |
76,559 |
2.39 |
5% |
|
| Ostronic Francis Patrick |
Director |
• • – |
2021-04-12 |
4 |
B |
$7.00 |
$35,000 |
D/D |
5,000 |
66,559 |
2.39 |
6% |
|
| Sieger Markus |
Director |
• • – |
2021-03-29 |
4 |
B |
$8.10 |
$81,000 |
D/D |
10,000 |
67,614 |
2.39 |
16% |
|
| Hrynkow Sharon Hemond |
Chief Scientific Officer |
• • – |
2021-03-29 |
4 |
B |
$7.46 |
$7,460 |
D/D |
1,000 |
18,350 |
2.74 |
16% |
|
| Ostronic Francis Patrick |
Director |
• • – |
2021-03-29 |
4 |
B |
$7.40 |
$22,600 |
D/D |
3,000 |
61,559 |
2.39 |
16% |
|
| Fine Joshua M |
Chief Financial Officer |
• • – |
2021-03-29 |
4 |
B |
$7.40 |
$370 |
D/D |
50 |
16,900 |
2.66 |
16% |
|
| Tate Jeffrey |
Chief Operating Officer |
• • – |
2021-03-29 |
4 |
B |
$7.50 |
$15,000 |
D/D |
2,000 |
27,160 |
2.81 |
16% |
|
| Toig Randall M. |
Director |
• • – |
2021-03-05 |
4 |
OE |
$5.00 |
$50,000 |
D/D |
10,000 |
44,078 |
|
- |
|
| Sieger Markus |
Director |
• • – |
2021-01-26 |
4 |
B |
$6.60 |
$14,527 |
D/D |
2,201 |
57,614 |
2.39 |
41% |
|
| Sieger Markus |
Director |
• • – |
2021-01-25 |
4 |
B |
$6.20 |
$49,108 |
D/D |
7,799 |
55,413 |
2.39 |
35% |
|
| Lisjak Michael Eric |
Chief Regulatory Officer |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
12,400 |
|
- |
|
| Fine N Scott |
Chief Executive Officer |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
109,666 |
|
- |
|
| Tate Jeffrey |
Chief Operating Officer |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
25,160 |
|
- |
|
| Hrynkow Sharon Hemond |
Chief Scientific Officer |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
17,350 |
|
- |
|
| Fine Joshua M |
Chief Financial Officer |
• • – |
2021-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
16,850 |
|
- |
|
| Ostronic Francis Patrick |
Director |
• • – |
2020-12-17 |
4 |
B |
$4.55 |
$139,748 |
D/D |
30,000 |
58,559 |
2.39 |
72% |
|
| Toig Randall M. |
Director |
• • – |
2020-12-11 |
4 |
B |
$0.00 |
$0 |
D/D |
10,000 |
34,078 |
2.31 |
68% |
|
| Hrynkow Sharon Hemond |
Chief Scientific Officer |
• • – |
2020-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
7,350 |
|
- |
|
| Tate Jeffrey |
Chief Operating Officer |
• • – |
2020-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
15,160 |
|
- |
|
| Shanahan William S |
Director |
• • – |
2020-12-11 |
4 |
B |
$0.00 |
$0 |
D/D |
20,000 |
63,677 |
2.31 |
68% |
|
| Sieger Markus |
Director |
• • – |
2020-12-11 |
4 |
B |
$0.00 |
$0 |
D/D |
15,000 |
72,729 |
2.31 |
68% |
|
| Fine N Scott |
Chief Executive Officer |
• • – |
2020-12-11 |
4 |
B |
$0.00 |
$0 |
D/D |
20,000 |
99,666 |
2.73 |
68% |
|
| Fine Joshua M |
Chief Financial Officer |
• • – |
2020-11-25 |
4 |
B |
$0.08 |
$1,125 |
D/D |
15,000 |
685,000 |
2.66 |
18% |
|
| Fine Joshua M |
Chief Financial Officer |
• • – |
2020-11-23 |
4 |
B |
$0.08 |
$799 |
D/D |
10,000 |
670,000 |
2.66 |
0% |
|
85 Records found
|
|
Page 1 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.02 (1.64%) 
